Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
11:40am, Friday, 15'th May 2026
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
10:16am, Friday, 15'th May 2026
PAVmed Inc. (PAVM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $2.1 per share a year ago.
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
08:00am, Friday, 15'th May 2026
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
08:00am, Thursday, 14'th May 2026
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement mile
Will PAVmed Inc. (PAVM) Report Negative Earnings Next Week? What You Should Know
11:01am, Friday, 08'th May 2026
PAVmed (PAVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
08:31am, Friday, 01'st May 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, ope
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
08:31am, Thursday, 30'th Apr 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
10:23am, Friday, 24'th Apr 2026
NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
08:30am, Thursday, 23'rd Apr 2026
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
PAVmed (NASDAQ:PAVM) Shares Pass Below 50-Day Moving Average – Time to Sell?
04:04am, Thursday, 23'rd Apr 2026
PAVmed Inc. (NASDAQ: PAVM - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $9.86 and traded as low as $9.1
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
08:01am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVme
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch
12:06pm, Tuesday, 07'th Apr 2026
PAVmed taps industry veteran Joseph Virgilio to lead its device portfolio relaunch to boost growth, commercialization and long-term shareholder value.
Treace Medical Concepts (NASDAQ:TMCI) and PAVmed (NASDAQ:PAVM) Head-To-Head Survey
01:01am, Tuesday, 07'th Apr 2026
PAVmed (NASDAQ: PAVM - Get Free Report) and Treace Medical Concepts (NASDAQ: TMCI - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two b
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
08:01am, Thursday, 02'nd Apr 2026
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
01:42pm, Monday, 30'th Mar 2026
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
